Evaluating the efficacy of evogliptin for aortic stenosis
The purpose of this study is to evaluate evogliptin for aortic stenosis (AS). AS is caused by progressive thickening and calcification of the aortic valve leaflets which leads to a reduction in aortic valve opening. Valve replacement is currently the only known treatment for this condition once it becomes severe enough to cause symptoms. No treatment has been found to date that can delay the progression of this disease.